Silicosis causes

Silicosis Causes

Unlike lung diseases that have multiple contributing factors or causes, silicosis results solely from inhaling crystalline silica dust. When this dust settles in the lungs, it causes inflammation and scarring, which gradually hardens and stiffens the lungs and makes it progressively more difficult to breathe.

The most common form of crystalline silica is quartz, which is found in sand, gravel, clay, granite and other types of rock. Silicosis is thus an occupational lung disease, as the majority of people who come into contact with these materials do so through their line of work. Individuals who may be particularly at risk for developing silicosis include the following:

  • Abrasives manufacturers
  • Asphalt/cement/concrete manufacturers
  • Ceramics manufacturers
  • Construction workers (including building and road construction)
  • Demolition workers
  • Foundry workers
  • Gemstone engineers
  • Glassmakers
  • Masons
  • Miners
  • Potters
  • Quarry workers
  • Rock crushers/drillers
  • Sandblasters
  • Silica millers
  • Steel industry workers
  • Stonecutters
  • Tunnel workers

Because the sand in Afghanistan and Iraq contains an irritant that causes silicosis when inhaled, U.S. soldiers who serve in those countries may also be at risk for developing this condition.

Inhaling any amount of silica can lead to the development of silicosis, but frequent or prolonged exposure causes an increased risk. There are three types of silicosis, which are differentiated by the amount of time it takes for the condition to develop. Chronic silicosis is the most common form, typically occurring at least 10 years after inhaling a relatively low amount of silica. Accelerated silicosis develops more quickly — generally within 5 to 10 years — following a higher level of exposure. Acute silicosis can develop within weeks or months after inhaling a very high amount of silica.

While there are many treatment methods that can help relieve the symptoms associated with silicosis, the cellular therapy offered at the Lung Institute is aimed at addressing the underlying causes of silicosis as well as symptoms. Please contact us today at 888-745-6697 to discuss how this alternative treatment may help you breathe easier.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.